Eakin, Amanda, Bustard, Michael, McGeough, Cathy, Ahmed, Tahanver, Bjourson, AJ and Gibson, David (2016) Siglec 1 and 2 as potential biomarkers in autoimmune disease. Proteomics Clinical Applications, TBC . [Journal article]
Full text not available from this repository.
Autoimmune diseases (AD) are currently treated with anti-inflammatory and immunosuppressive drugs, aimed at reducing symptoms of disease in order to improve quality of life for patients. However, for a significant number of patients these therapies are ineffective, leading to an increased risk of irreversible damage and eventual disability in certain cases. Growing evidence has implicated glycosylated proteins and their cognate receptors in modulation of the autoimmune response. This review will summarise these findings with particular focus on Siglec-1 and -2 involvement in AD. Fluctuations in these glycosylation dependent pathways could act as sentinels of disease activity or drug responses. If validated, protein modification and cellular response markers could help clinicians achieve remission earlier.
|Item Type:||Journal article|
|Keywords:||Glycosylation, Immune tolerance, Siglec|
|Faculties and Schools:||Faculty of Life and Health Sciences > School of Biomedical Sciences|
Faculty of Life and Health Sciences
|Research Institutes and Groups:||Biomedical Sciences Research Institute|
Biomedical Sciences Research Institute > Stratified Medicine
|Deposited By:||Dr David Gibson|
|Deposited On:||28 Jan 2016 12:08|
|Last Modified:||28 Jan 2016 12:08|
Repository Staff Only: item control page